

IN THE SPECIFICATION

**AMENDMENTS TO THE SPECIFICATION**

1. Please amend paragraph 18 as follows:

[0018] or a bombesin analog according to the formula:

-Gln-Trp-Ala-Ala- $\beta$ Ala -His-Phe-Nle-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val-Gly-His-Leu- $\Psi$ (CH<sub>2</sub>-NH)-Leu-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val-Gly-His-Leu- $\Psi$ (CH<sub>2</sub>-NH)-Phe-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val- $\beta$ Ala-His-Leu-Leu-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val- $\beta$ Ala-His-Leu-Nle-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val- $\beta$ Ala-His-Phe-Nle-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val- $\beta$ Ala -His-Ala-Nle-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val- $\beta$ Ala -Ala-Phe-Nle-NH<sub>2</sub>;  
-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH<sub>2</sub>; (SEQ ID NO: 91)  
-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>; (SEQ ID NO: 402)  
-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH<sub>2</sub>; (SEQ ID NO: 443)  
-DAla-Gln-Trp-Ala-Val- $\beta$ Ala-His-Phe-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Ala- $\beta$ Ala-His-Phe-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val- $\beta$ Ala-Ala-Phe-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val- $\beta$ Ala-His-Phe-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val- $\beta$ Ala-His-Phe-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val- $\beta$ Ala-His-Ala-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val- $\beta$ Ala-His-Leu-Leu-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val- $\beta$ Ala-His-Leu-Nle-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu- $\Psi$ (CH<sub>2</sub>-NH)-Leu-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu- $\Psi$ (CH<sub>2</sub>-NH)-Phe-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH<sub>2</sub>;  
-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH<sub>2</sub>; or

or a pharmaceutically acceptable salt thereof.

2. On page 90 of the specification, please amend the last two sequences as follows:

-HSDAVFTDNYTRLRKQMAVKLLNSILN-NH<sub>2</sub> (SEQ ID NO: 454)  
-HSDAVFTDNYTRLRKQMAVKKALNSILN-NH<sub>2</sub> (SEQ ID NO: 465)

3. On page 91 of the specification, please amend the first two sequences as follows:

-HSDAVFTDNYTRLRKQMAVKFLNSILN-NH<sub>2</sub> (SEQ ID NO: 476)

-HSDAVFTDNYTRLRKQMAVKYLNSILN-NH<sub>2</sub> (SEQ ID NO: 487)

4. On page 127 of the specification, please amend the sequences as follows:

-HSDAVFTDNYTRLRKQMAVKYLNSILN-NH<sub>2</sub> (SEQ ID NO: 487)  
-HSDAVFTDNYTRLRKQMAVKKFLNSILN-NH<sub>2</sub> (SEQ ID NO: 476)  
-HSDAVFTDNYTRLRKQMAVKKALNSILN-NH<sub>2</sub> (SEQ ID NO: 465)  
-HSDAVFTDNYTRLRKQMAVKKLLNSILN-NH<sub>2</sub> (SEQ ID NO: 454)

5. On page 183 of the specification, please amend the sequences as follows:

-HSDAVFTDNYTRLRKQMAVKYLNSILN-NH<sub>2</sub> (SEQ ID NO: 487)  
-HSDAVFTDNYTRLRKQMAVKKALNSILN-NH<sub>2</sub> (SEQ ID NO: 465)  
-HSDAVFTDNYTRLRKQMAVKKLLNSILN-NH<sub>2</sub> (SEQ ID NO: 454)

6. Please delete the original Sequence Listing and insert the Substitute Sequence Listing included herewith.